Here, we investigate how orthotopic grafts of KrasG12D-driven NSCLC cells respond to a clinically relevant Ezh2 inhibitor and investigate the adaptive response mechanisms with a view toward selectively exploiting chemotherapy to target acquired vulnerabilities in a sequential or “neoadjuvant-like” dosing scheme. The gene discussed is EZH2; the disease is non-small cell lung carcinoma.